Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Comparative efficacy of 1% terbinafine hydrochloride cream and 1% ciclopirox olamine cream alone and in combination for the treatment of dermatophytosis

Karan Chhabra, Yash Pal Mitra, Rattan Lal Bassan.




Abstract

Background: Various antifungal agents, both in oral and topical forms, have been developed for the treatment of dermatophytosis.

Aims and Objectives: The aims of this study were to evaluate the efficacy of 1% terbinafine hydrochloride cream and 1% ciclopirox olamine cream alone and in combination in the treatment of dermatophytosis.

Materials and Methods: A randomized and comparative study was done at the Department of Dermatology, Government Medical College and Hospital, Chandigarh. Sixty patients of clinically diagnosed tinea corporis/tinea cruris/tinea faciei, attending the outpatient department will be allocated to three therapeutic groups of 20 patients each using random tables. Group 1: Topical 1% terbinafine hydrochloride cream twice daily for 6 weeks. Group 2: Topical 1% ciclopirox olamine cream twice daily for 6 weeks. Group 3: Topical 1% terbinafine hydrochloride cream once daily in the morning and 1% ciclopirox olamine cream once daily in the evening for 6 weeks. Inclusion criteria: (i) Body Surface Area –

Key words: Ciclopirox Olamine; Dermatophytosis; Terbinafine Hydrochloride






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.